HC Wainwright & Co. Maintains Buy on Ikena Oncology, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Ikena Oncology (NASDAQ:IKNA) but has lowered the price target from $11 to $4.

May 29, 2024 | 10:36 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Ikena Oncology but has significantly lowered the price target from $11 to $4, indicating a more cautious outlook.
The significant reduction in the price target from $11 to $4 suggests a more cautious outlook on Ikena Oncology's future performance, which could negatively impact investor sentiment and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100